Genome editing of factor X in zebrafish reveals unexpected tolerance of severe defects in the common pathway

Hu, Z., Liu, Y., Huarng, M.C., Menegatti, M., Reyon, D., Rost, M.S., Norris, Z.G., Richter, C.E., Stapleton, A.N., Chi, N.C., Peyvandi, F., Joung, J.K., Shavit, J.A.
Blood   130(5): 666-676 (Journal)
Registered Authors
Chi, Neil C., Hu, Zhilian, Liu, Yang, Richter, Catherine, Rost, Megan, Shavit, Jordan
MeSH Terms
  • Animals
  • Blood Coagulation/genetics*
  • Factor X*/genetics
  • Factor X*/metabolism
  • Factor X Deficiency/embryology
  • Factor X Deficiency/genetics
  • Gene Editing*
  • Humans
  • Mice
  • Mutation*
  • Zebrafish*/embryology
  • Zebrafish*/genetics
  • Zebrafish Proteins*/genetics
  • Zebrafish Proteins*/metabolism
28576875 Full text @ Blood
Deficiency of factor X (F10) in humans is a rare bleeding disorder with a heterogeneous phenotype and limited therapeutic options. Targeted disruption of F10 and other common pathway factors in mice results in embryonic/neonatal lethality with rapid resorption of homozygous mutants, hampering additional studies. Several of these mutants also display yolk sac vascular defects, suggesting a role for thrombin signaling in vessel development. The zebrafish is a vertebrate model that demonstrates conservation of the mammalian hemostatic and vascular systems. We have leveraged these advantages for in-depth study of the role of the coagulation cascade in the developmental regulation of hemostasis and vasculogenesis. In this article, we show that ablation of zebrafish f10 by using genome editing with transcription activator-like effector nucleases results in a major embryonic hemostatic defect. However, widespread hemorrhage and subsequent lethality does not occur until later stages, with absence of any detectable defect in vascular development. We also use f10-/- zebrafish to confirm 5 novel human F10 variants as causative mutations in affected patients, providing a rapid and reliable in vivo model for testing the severity of F10 variants. These findings as well as the prolonged survival of f10-/- mutants will enable us to expand our understanding of the molecular mechanisms of hemostasis, including a platform for screening variants of uncertain significance in patients with F10 deficiency and other coagulation disorders. Further study as to how fish tolerate what is an early lethal mutation in mammals could facilitate improvement of diagnostics and therapeutics for affected patients with bleeding disorders.
Genes / Markers
Show all Figures
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Engineered Foreign Genes